Literature DB >> 24853045

In-utero infection with HIV-1 associated with suppressed lymphoproliferative responses at birth.

B Lohman-Payne1, T Sandifer, M OhAinle, C Crudder, J Lynch, M M Omenda, J Maroa, K Fowke, G C John-Stewart, C Farquhar.   

Abstract

In-utero exposure to HIV-1 may affect the immune system of the developing child and may induce HIV-1-specific immune responses, even in the absence of HIV-1 infection. We evaluated lymphoproliferative capacity at birth among 40 HIV-1-uninfected infants born to HIV-1-infected mothers and 10 infants who had acquired HIV-1 in utero. Cord blood mononuclear cells were assayed using [(3) H]-thymidine incorporation for proliferation in response to HIV-1 p55-gag and the control stimuli phytohaemagglutinin (PHA), Staphylococcus enterotoxin B (SEB) and allogeneic cells. In response to HIV-1 p55-gag, eight (20%) HIV-1-exposed, uninfected (EU) infants had a stimulation index (SI) ≥ 2 and three (30%) in-utero HIV-1 infected infants had SI ≥2. The frequency and magnitude of responses to HIV-1 p55-gag were low overall, and did not differ statistically between groups. However, proliferative responses to control stimuli were significantly higher in EU infants than in infants infected in utero, with a median SI in response to PHA of 123 [interquartile range (IQR) 77-231] versus 18 (IQR 4-86) between EU and infected infants, respectively (P < 0·001). Among infected infants, gestational maturity was associated with the strength of HIV-1 p55-gag response (P < 0·001); neither maternal nor infant HIV-1 viral load was associated. In summary, EU and HIV-1-infected infants mounted HIV-1-specific lymphoproliferative responses at similar rates (20-30%), and although global immune function was preserved among EU infants, neonatal immune responses were significantly compromised by HIV-1 infection. Such early lymphoproliferative compromise may, in part, explain rapid progression to AIDS and death among HIV-1-infected infants.
© 2014 British Society for Immunology.

Entities:  

Keywords:  Candida; SEB; allogenic; gestational age; p55gag

Mesh:

Year:  2014        PMID: 24853045      PMCID: PMC4360198          DOI: 10.1111/cei.12386

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  46 in total

1.  Proliferation responses to HIVp24 during antiretroviral therapy do not reflect improved immune phenotype or function.

Authors:  Christoph G Lange; Zhan Xu; Bruce K Patterson; Kathy Medvik; Brooke Harnisch; Robert Asaad; Hernan Valdez; Sandra J Lee; Alan Landay; Judy Lieberman; Michael M Lederman
Journal:  AIDS       Date:  2004-03-05       Impact factor: 4.177

2.  Altered immunological reactivity in HIV-1-exposed uninfected neonates.

Authors:  Joana Hygino; Patrícia G Lima; Renato G S Filho; Agostinho A L Silva; Carmen S M Saramago; Regis M Andrade; Daniel M Andrade; Arnaldo F B Andrade; Rodrigo Brindeiro; Amilcar Tanuri; Cleonice A M Bento
Journal:  Clin Immunol       Date:  2008-03-19       Impact factor: 3.969

3.  Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging.

Authors:  M Clerici; N I Stocks; R A Zajac; R N Boswell; D R Lucey; C S Via; G M Shearer
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

4.  Clinical assessment of gestational age in the newborn infant.

Authors:  L M Dubowitz; V Dubowitz; C Goldberg
Journal:  J Pediatr       Date:  1970-07       Impact factor: 4.406

5.  Transfer of maternal specific cell-mediated immunity to the fetus.

Authors:  H F Pabst; J C Godel; D W Spady; K Cho
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

6.  Age-related changes in intracellular TH1/TH2 cytokine production, immunoproliferative T lymphocyte response and natural killer cell activity in newborns, children and adults.

Authors:  Antonella Gasparoni; Laura Ciardelli; Antonia Avanzini; Anna Maria Castellazzi; Roberta Carini; Giorgio Rondini; Gaetano Chirico
Journal:  Biol Neonate       Date:  2003

7.  Predictors of early mortality in a cohort of human immunodeficiency virus type 1-infected african children.

Authors:  Elizabeth M Obimbo; Dorothy A Mbori-Ngacha; James O Ochieng; Barbra A Richardson; Phelgona A Otieno; Rose Bosire; Carey Farquhar; Julie Overbaugh; Grace C John-Stewart
Journal:  Pediatr Infect Dis J       Date:  2004-06       Impact factor: 2.129

8.  Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection.

Authors:  Barbra A Richardson; Dorothy Mbori-Ngacha; Ludo Lavreys; Grace C John-Stewart; Ruth Nduati; Dana D Panteleeff; Sandra Emery; Joan K Kreiss; Julie Overbaugh
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

9.  Deficient human immunodeficiency virus type 1-specific cytotoxic T cell responses in vertically infected children.

Authors:  K Luzuriaga; R A Koup; C A Pikora; D B Brettler; J L Sullivan
Journal:  J Pediatr       Date:  1991-08       Impact factor: 4.406

10.  Longitudinal study of 94 symptomatic infants with perinatally acquired human immunodeficiency virus infection. Evidence for a bimodal expression of clinical and biological symptoms.

Authors:  S Blanche; M Tardieu; A Duliege; C Rouzioux; F Le Deist; K Fukunaga; M Caniglia; C Jacomet; A Messiah; C Griscelli
Journal:  Am J Dis Child       Date:  1990-11
View more
  2 in total

Review 1.  Impact of maternal HIV exposure, feeding status, and microbiome on infant cellular immunity.

Authors:  Sonwabile Dzanibe; Heather B Jaspan; Michael Z Zulu; Agano Kiravu; Clive M Gray
Journal:  J Leukoc Biol       Date:  2018-12-21       Impact factor: 4.962

Review 2.  Understanding Viral and Immune Interplay During Vertical Transmission of HIV: Implications for Cure.

Authors:  Omayma Amin; Jenna Powers; Katherine M Bricker; Ann Chahroudi
Journal:  Front Immunol       Date:  2021-10-21       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.